{
  "first_published_at": "2010-12-07", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON102838", 
  "title": "Fibrates: European Medicines Agency concludes first-line treatment is not recommended", 
  "tags": "{\"parsed_therapeutic\": [\"cardiovascular-disease-lipidology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Cardiovascular disease and lipidology\"]}", 
  "_document_number": 172, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/dose_icon.png", 
  "therapeutic_area": [
    "cardiovascular-disease-lipidology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Fibrates: European Medicines Agency concludes first-line treatment is not recommended</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: December 2010</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Healthcare professionals should not prescribe fibrates to newly diagnosed patients as first-line treatment, except for those with severe hypertriglyceridaemia or those who cannot take statins.-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>The European Medicines Agency's Committee for Medicinal Products for Human Use has concluded that the benefits of the four <strong>fibrates</strong>&mdash;bezafibrate, ciprofibrate, fenofibrate, and gemfibrozil&mdash;continue to outweigh the risks in the treatment of patients with blood-lipid disorders. However, healthcare professionals should not prescribe them to newly diagnosed patients as first-line treatment, except for those with severe hypertriglyceridaemia or those who cannot take statins.</p><p><strong>Further information:</strong><br></p><p>Prescribing advice for fibrates can be found in the <a href=\"ssLINK/CON079321\" target=\"_blank\">November 2007 issue of Drug Safety Update</a></p><p><a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/10/news_detail_001135.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1\" target=\"_blank\">European Medicines Agency press release</a></p><p><a href=\"http://www.npci.org.uk/therapeutics/cardio/cdlipids/workshops/workshop_60minute_elearn_event1.php\" target=\"_blank\">National Prescribing Centre information on lipid management</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Dec 2010 vol 4 issue 5: S1.</em><br></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>The European Medicines Agency's Committee for Medicinal Products for Human Use has concluded that the benefits of the four <strong>fibrates</strong>&#8212;bezafibrate, ciprofibrate, fenofibrate, and gemfibrozil&#8212;continue to outweigh the risks in the treatment of patients with blood-lipid disorders. However, healthcare professionals should not prescribe them to newly diagnosed patients as first-line treatment, except for those with severe hypertriglyceridaemia or those who cannot take statins.</p><p><strong>Further information:</strong><br></p><p>Prescribing advice for fibrates can be found in the <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON079321\" target=\"_blank\">November 2007 issue of Drug Safety Update</a></p><p><a href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/10/news_detail_001135.jsp&amp;murl=menus/news_and_events/news_and_events.jsp&amp;mid=WC0b01ac058004d5c1\" target=\"_blank\">European Medicines Agency press release</a></p><p><a href=\"http://www.npci.org.uk/therapeutics/cardio/cdlipids/workshops/workshop_60minute_elearn_event1.php\" target=\"_blank\">National Prescribing Centre information on lipid management</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update Dec 2010 vol 4 issue 5: S1.</em><br></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2010-12-01", 
  "date_last_modified": "2010-12-09", 
  "_assets": [], 
  "_item_id": 172, 
  "summary": "", 
  "body": "Article date: December 2010\n\nThe European Medicines Agency's Committee for Medicinal Products for Human Use has concluded that the benefits of the four fibrates—bezafibrate, ciprofibrate, fenofibrate, and gemfibrozil—continue to outweigh the risks in the treatment of patients with blood-lipid disorders. However, healthcare professionals should not prescribe them to newly diagnosed patients as first-line treatment, except for those with severe hypertriglyceridaemia or those who cannot take statins.\n\nFurther information:  \n\n\nPrescribing advice for fibrates can be found in the [November 2007 issue of Drug Safety Update](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON079321)\n\n[European Medicines Agency press release](http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/10/news_detail_001135.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1)\n\n[National Prescribing Centre information on lipid management](http://www.npci.org.uk/therapeutics/cardio/cdlipids/workshops/workshop_60minute_elearn_event1.php)\n\n \n\nArticle citation: Drug Safety Update Dec 2010 vol 4 issue 5: S1.  \n\n"
}